|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||301.20 - 314.00|
|52-week range||65.40 - 396.90|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||65.76|
|Earnings date||09 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Dr. Manish Garg, Emergency Medicine Physician & Co-Founder of World Academic Council of Emergency Medicine, joins Yahoo Finance to discus the spread of the Omicron COVID-19 variant.
Columbia University professor Meg Fitzgerald speaks with Yahoo Finance Live about the uncertainty surrounding Omicron, the effectiveness (or lack thereof) of travel bans, the demand for booster shots, global vaccination rates, and the strained U.S. health care system.
On yet more worrying news about the omicron variant of the coronavirus, the fortunes of coronavirus stocks were mixed on Tuesday. In contrast the co-developer of Pfizer's jab, BioNTech (NASDAQ: BNTX), was down by almost 3%. It's interesting that the fortunes of partners Pfizer and BioNTech, which together developed the Comirnaty vaccine, were diverging so sharply.